burosumab
Selected indexed studies
- Burosumab. (, 2012) [PMID:31643797]
- Burosumab for Pediatric X-Linked Hypophosphatemia. (Curr Osteoporos Rep, 2021) [PMID:33970403]
- Burosumab. (, 2006) [PMID:30000040]
_Worker-drafted node — pending editorial review._
Connections
burosumab is a side effect of
Sources
- Burosumab for Pediatric X-Linked Hypophosphatemia. (2021) pubmed
- Efficacy and Safety of Burosumab in X-linked Hypophosphatemia. (2023) pubmed
- A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. (2018) pubmed
- Burosumab. (2012) pubmed
- Burosumab. (2006) pubmed
- Burosumab: Current status and future prospects. (2024) pubmed
- Burosumab: First Global Approval. (2018) pubmed
- Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. (2019) pubmed
- PMID:39913656 (2024) pubmed
- Burosumab for X-linked hypophosphataemia. (2022) pubmed